–%
Finnrick rating
Not enough classifiable CJC-1295 tests from this vendor yet.
methodology · Purity focus
Finnrick analysis · CJC-1295

PurePeptides' purity-focus record is strongest on Tirzepatide, where identity, purity, and fill stay inside limits despite earlier overfills and later COAs lacking batch IDs. Retatrutide is mostly clean but drifting on fill with a recent large overfill, while Ipamorelin is the weak spot with repeated low purity, short fills, and thin batch breadth.

methodology →
vendor intelligence report
Vendor Intelligence Report: PurePeptides

We investigated who actually operates PurePeptides — corporate records, ownership trails, web infrastructure, and how its lab results break down product by product. Read the full report before you order.

32 pages6 risk factors assessed13 Jun 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
Tirzepatide
$9.50
83%
6
2
Retatrutide
$11.00
75%
7
3
Ipamorelin
$10.00
56%
4
Contact channels
Showing CJC-1295 tests only
PurePeptides CJC-1295 test history
No published tests for this pair yet.

About PurePeptides test results from Finnrick

PurePeptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 3 peptides and 17 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible PurePeptides peptides in this dataset are CJC-1295 (0 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 17 recent tests.

Corrections
No corrections.